Naaz Farah, Mohanty Partha Sarathi, Bansal Avi Kumar, Kumar Dilip, Gupta Umesh Datta
Department of Microbiology and Molecular Biology, National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, Uttar Pradesh, India.
Department of Division of Clinics, National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, Uttar Pradesh, India.
Int J Mycobacteriol. 2017 Jul-Sep;6(3):222-228. doi: 10.4103/ijmy.ijmy_70_17.
Every year >200,000 new leprosy cases are registered globally. This number has been fairly stable over the past 8 years. The World Health Organization has set a target to interrupt the transmission of leprosy globally by 2020. It is important, in terms of global action and research activities, to consider the eventuality of multidrug therapy (MDT) resistance developing. It is necessary to measure disease burden comprehensively, and contact-centered preventive interventions should be part of a global elimination strategy. Drug resistance is the reduction in effectiveness of a drug such as an antimicrobial or an antineoplastic in curing a disease or condition. MDT has proven to be a powerful tool in the control of leprosy, especially when patients report early and start prompt treatment. Adherence to and its successful completion is equally important. This paper has reviewed the current state of leprosy worldwide and discussed the challenges and also emphasizes the challenge beyond the elimination in leprosy.
全球每年登记的新麻风病例超过20万例。这一数字在过去8年一直相当稳定。世界卫生组织设定了到2020年在全球阻断麻风传播的目标。就全球行动和研究活动而言,考虑多药疗法(MDT)出现耐药性的可能性很重要。全面衡量疾病负担很有必要,以接触者为中心的预防性干预措施应成为全球消除战略的一部分。耐药性是指一种药物(如抗菌药或抗肿瘤药)在治愈疾病或病症方面有效性的降低。MDT已被证明是控制麻风的有力工具,尤其是当患者早报告并尽早开始治疗时。坚持治疗并成功完成治疗同样重要。本文回顾了全球麻风的现状,讨论了挑战,并强调了麻风消除之后的挑战。